Close Menu


A separate deal under which Prometheus agreed to acquire 2 million shares of Rosetta at $4 per share has also been completed.

The system, which serves California's largest public healthcare district, is offering 23andMe's service at several outpatient centers in an effort to advance preventative care.

The university's new labs will conduct an array of 'omics studies of cancer, addiction, infection, and others.

New Releases: Apr 29, 2009


Matrix Genomics' DNA home testing kits for Alzheimer's disease, breast cancer, and heart attack risk

Moving Target: CNVs in Disease


More and more research is linking CNVs to disease. It's not only changing the way scientists study disease, but also how clinicians diagnose it.

The university will compare the genomes of dyslexic and non-dyslexic people to study language gene interactions and develop a diagnostic test.

PGx & molecular Dx

Upcoming events

SeqWright will offer the test, which evaluates a patient's responsiveness to hair-loss treatment finasteride, through its CLIA lab.

BioArray Briefs: Apr 28, 2009


23andMe, Palomar Pomerado Health, Sequenom, Satoris, RayBiotech, University of Griefswald, InforSense, Institute of Molecular and Medical Genetics, CapitalBio, BioTools


An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.